Peptide-coated skin substitutes for the treatment of burn injuries and wounds

用于治疗烧伤和伤口的肽涂层皮肤替代品

• 批准号: 8312066
• 负责人: Bruce Lamb
• 金额: $ 30.65万
• 依托单位: AFFINERGY, LLC
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2014-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8312066
• 关键词: Acute; Address; Adipose tissue; Affinity; Animal Model; Animals; Anti-Inflammatory Agents; Anti-inflammatory; Apoptosis; Attenuated; Autologous; Autologous Transplantation; Binding; Blood Vessels; Bone Marrow; Burn injury; Cell Transplants; Cells; Cellular Infiltration; Cessation of life; Chemistry; Chronic; Clinical; Collagen; Cultured Cells; Deposition; Dermal; Dermis; Devices; Diabetes Mellitus; Extracellular Matrix; Family suidae; Fibroblasts; Goals; Granulation Tissue; Growth Factor; Harvest; Healed; Healthcare Systems; Histology; Hospitalization; Hypertrophic Cicatrix; Immune; Immune response; Implant; Infection; Infiltration; Inflammation; Inflammatory Response; Left; Life; Link; Marketing; Measures; Mechanics; Medical; Mesenchymal Stem Cells; Operative Surgical Procedures; Outcome; Pain; Patients; Peptides; Phage Display; Pharmaceutical Preparations; Phase; Phenotype; Procedures; Process; Property; Proteins; Relative (related person); Reporting; Risk; Safety; Screening procedure; Skin; Skin Substitutes; Societies; Specificity; Stem cells; Surgical sutures; Tensile Strength; Testing; Time; Tissues; Treatment Efficacy; Varicose Ulcer; Vascularization; Wound Healing; attenuation; biomaterial compatibility; burn therapy; cost; foot; healing; implantation; improved; in vivo; meetings; mortality; neovascularization; point of care; pre-clinical; protein aminoacid sequence; prototype; research study; success; wound

DESCRIPTION (provided by applicant): Burn injuries and chronic wounds present a significant burden to patients and the US healthcare system. Each year in the US, there are 450,000 burns that require medical treatment and 45,000 burns that require hospitalization. One of the most common causes of chronic wounds, venous ulcers, occurs in 600,000 to 1,500,000 US patients; 15% to 20% of patients with diabetes will suffer a chronic foot wound. For burn injuries, the mortality rate can be as high as 10%, with 75% of patient deaths arising from infection. Increased risk of infection after burn injury can be attributed to multiple factors including slow wound healing. In addition to the risk of infection, delays in burn wound closure prolong pain, increase the chance of hypertrophic scarring, and multiply the number of operative procedures. Stem cells can address the unmet needs in burn therapy by accelerating the rate of vascularization and collagen deposition and by attenuating the inflammatory response. Adipose-derived mesenchymal stem cells (ASCs) and bone marrow-derived mesenchymal stem cells (BMSCs) secrete a broad range of proteins that are crucial for neovascularization, extracellular matrix (ECM) remodeling, and the attenuation of an inflammatory response. Multiple pre-clinical and clinical reports suggest that ASCs and BMSCs improve healing of burn injuries and acute and chronic wounds. However, the use of expanded and cultured cells increases the time and cost of medical procedures and can delay treatment. Therefore, a product that can capture large numbers of ASCs or BMSCs from autologous tissue at the point-of- care would have significant advantages over the use of cultured cells. In this project, we propose to develop a peptide coating for skin substitutes to capture and retain ASCs at the point-of-care. When used to replace damaged skin, the peptide-coated skin substitute will accelerate vascularization and healing and provide substantially better outcomes for patients. PUBLIC HEALTH RELEVANCE: Project Narrative Adult stem cells provide numerous advantages to speed up the process of healing of burn injuries and wounds. In this application, we propose to modify skin substitutes with a coating that will allow surgeons to capture adult stem cells onto the skin substitute during the operation. This cell capture will reduce the costs o processing cells, and the delivery of high numbers of therapeutic cells will provide better and faster healing.

描述（由申请人提供）：烧伤和慢性伤口给患者和美国医疗保健系统带来了重大负担。在美国，每年有450，000例烧伤需要治疗，45，000例烧伤需要住院治疗。慢性伤口的最常见原因之一，静脉溃疡，发生在600，000至1，500，000名美国患者中; 15%至20%的糖尿病患者将遭受慢性足部伤口。对于烧伤，死亡率可高达10%，其中75%的患者死亡是由感染引起的。烧伤后感染的风险增加可归因于多种因素，包括伤口愈合缓慢。除了感染的风险外，烧伤伤口闭合延迟会延长疼痛，增加肥厚性瘢痕形成的机会，并增加手术次数。干细胞可以通过加速血管化和胶原沉积的速率以及通过减弱炎症反应来解决烧伤治疗中未满足的需求。脂肪来源的间充质干细胞（ASC）和骨髓来源的间充质干细胞（BMSC）分泌对于新血管形成、细胞外基质（ECM）重塑和减轻炎症反应至关重要的广泛蛋白质。多项临床前和临床报告表明，ASCs和BMSCs可改善烧伤和急性及慢性伤口的愈合。然而，使用扩增和培养的细胞增加了医疗程序的时间和成本，并可能延误治疗。因此，可以在护理点从自体组织中捕获大量ASC或BMSC的产品将比使用培养的细胞具有显著的优势。在这个项目中，我们建议开发一种用于皮肤替代品的肽涂层，以在护理点捕获和保留ASC。当用于替换受损皮肤时，肽涂层皮肤替代品将加速血管化和愈合，并为患者提供更好的结果。 公共卫生关系：成体干细胞在加速烧伤和创伤愈合过程中具有许多优势。在这个应用中，我们建议用涂层来修饰皮肤替代品，这将允许外科医生在手术过程中将成体干细胞捕获到皮肤替代品上。这种细胞捕获将降低处理细胞的成本，并且大量治疗细胞的递送将提供更好和更快的愈合。